These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 29435950)

  • 1. Evaluation of performance of distributed delay model for chemotherapy-induced myelosuppression.
    Krzyzanski W; Hu S; Dunlavey M
    J Pharmacokinet Pharmacodyn; 2018 Apr; 45(2):329-337. PubMed ID: 29435950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ordinary differential equation approximation of gamma distributed delay model.
    Krzyzanski W
    J Pharmacokinet Pharmacodyn; 2019 Feb; 46(1):53-63. PubMed ID: 30617672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transit and lifespan in neutrophil production: implications for drug intervention.
    Câmara De Souza D; Craig M; Cassidy T; Li J; Nekka F; Bélair J; Humphries AR
    J Pharmacokinet Pharmacodyn; 2018 Feb; 45(1):59-77. PubMed ID: 29236223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.
    Hansson EK; Wallin JE; Lindman H; Sandström M; Karlsson MO; Friberg LE
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):839-48. PubMed ID: 19680655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.
    Friberg LE; Henningsson A; Maas H; Nguyen L; Karlsson MO
    J Clin Oncol; 2002 Dec; 20(24):4713-21. PubMed ID: 12488418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
    Lum BL; Kaubisch S; Fisher GA; Brown BW; Sikic BI
    Cancer Chemother Pharmacol; 2000; 45(4):305-11. PubMed ID: 10755319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A distributed delay approach for modeling delayed outcomes in pharmacokinetics and pharmacodynamics studies.
    Hu S; Dunlavey M; Guzy S; Teuscher N
    J Pharmacokinet Pharmacodyn; 2018 Apr; 45(2):285-308. PubMed ID: 29368268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of myelotoxic effects of chemotherapy from early leukopenic response: application of a mathematical model for granulopoiesis.
    Blumenson LE; Bross ID
    J Surg Oncol; 1979; 11(2):171-6. PubMed ID: 439901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of ZL-004 on raising leukocyte count].
    Sun HY; Li CG; Xiao L; Wang GP; Liu QH
    Yao Xue Xue Bao; 2010 Jun; 45(6):797-800. PubMed ID: 20939193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats.
    Friberg LE; Freijs A; Sandström M; Karlsson MO
    J Pharmacol Exp Ther; 2000 Nov; 295(2):734-40. PubMed ID: 11046112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia.
    Hansson EK; Friberg LE
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):881-90. PubMed ID: 22057837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
    Hanada K; Asano K; Nishimura T; Chimata T; Matsuo Y; Tsuchiya M; Ogata H
    J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of 5-fluorouracil for erythropenia in rats.
    Kobuchi S; Ito Y; Hayakawa T; Nishimura A; Shibata N; Takada K; Sakaeda T
    J Pharmacol Toxicol Methods; 2014; 70(2):134-44. PubMed ID: 25072509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression.
    Antman KS; Griffin JD; Elias A; Socinski MA; Ryan L; Cannistra SA; Oette D; Whitley M; Frei E; Schnipper LE
    N Engl J Med; 1988 Sep; 319(10):593-8. PubMed ID: 3045544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased sensitivity of the automatic white precursor cell channel (WPC) for blast flagging in patients with leukopenia.
    Lee N; Jun JH; Lee DS
    Clin Biochem; 2016 Jun; 49(9):675-681. PubMed ID: 26800779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of synergy between 5-fluorouracil and interferon-gamma in the treatment of malignancy in the rat.
    Codde JP; Vines JA; van der Meide PH; Burton MA; Gray BN
    In Vivo; 1991; 5(4):413-7. PubMed ID: 1810431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial.
    Shpall EJ; Jones RB; Bast RC; Rosner GL; Vandermark R; Ross M; Affronti ML; Johnston C; Eggleston S; Tepperburg M
    J Clin Oncol; 1991 Jan; 9(1):85-93. PubMed ID: 1985173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics.
    Grochow LB; Noe DA; Ettinger DS; Donehower RC
    Cancer Chemother Pharmacol; 1989; 24(5):314-20. PubMed ID: 2758561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transfection with a bcl-2 expression vector protects transplanted bone marrow from chemotherapy-induced myelosuppression.
    Kondo S; Yin D; Morimura T; Oda Y; Kikuchi H; Takeuchi J
    Cancer Res; 1994 Jun; 54(11):2928-33. PubMed ID: 7514494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression.
    Robak T; Krykowski E; Warzocha K
    Arch Immunol Ther Exp (Warsz); 1992; 40(5-6):331-7. PubMed ID: 1340191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.